Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from An overview of potential inhibitors targeting non-structural proteins 3 (PL pro and Mac1) and 5 (3CL pro /M pro ) of SARS-CoV-2. Local targets link to admitted publications; unresolved targets remain external evidence.
SARS-CoV-2 is an appropriate name for the new coronavirus
10.1016/s0140-6736(20)30557-2 · 2020 · External reference
Unresolved reference
External reference
10.1038/s41586-020-2342-5
10.1038/s41586-020-2342-5 · External reference
Airborne transmission of SARS-CoV-2: theoretical considerations and available evidence
10.1001/jama.2020.12458 · 2020 · External reference
Neurologic features in severe SARS-CoV-2 infection
10.1056/nejmc2008597 · 2020 · External reference
10.1038/s41579-020-00459-7
10.1038/s41579-020-00459-7 · External reference
SARS-CoV-2: a time for clear and immediate action
10.1016/s1473-3099(20)30250-4 · 2020 · External reference
Predicting the impacts of epidemic outbreaks on global supply chains: a simulation-based analysis on the coronavirus outbreak (COVID-19/SARS-CoV-2) case
10.1016/j.tre.2020.101922 · 2020 · External reference
10.1093/nar/gky1069
10.1093/nar/gky1069 · External reference
10.1002/jmv.25681
10.1002/jmv.25681 · External reference
Virus-encoded proteinases and proteolytic processing in the Nidovirales
10.1099/0022-1317-81-4-853 · 2000 · External reference
10.1016/s0014-5793(03)01091-3
10.1016/s0014-5793(03)01091-3 · External reference
10.1021/acs.jproteome.0c00129
10.1021/acs.jproteome.0c00129 · External reference
Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules
10.1107/s0907444998009378 · 1998 · External reference
10.1093/nar/gkw329
10.1093/nar/gkw329 · External reference
10.1016/s0006-291x(03)01342-1
10.1016/s0006-291x(03)01342-1 · External reference
10.1016/j.peptides.2005.09.006
10.1016/j.peptides.2005.09.006 · External reference
10.1016/j.peptides.2004.06.018
10.1016/j.peptides.2004.06.018 · External reference
10.1016/j.chom.2020.02.001
10.1016/j.chom.2020.02.001 · External reference
10.1016/j.cell.2020.02.058
10.1016/j.cell.2020.02.058 · External reference
10.1016/j.lfs.2020.118056
10.1016/j.lfs.2020.118056 · External reference
Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition
2020 · External reference
Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
2020 · External reference
10.3389/fimmu.2021.647934
10.3389/fimmu.2021.647934 · External reference
10.1016/j.it.2020.09.004
10.1016/j.it.2020.09.004 · External reference
10.1080/14728222.2020.1820482
10.1080/14728222.2020.1820482 · External reference
10.1016/j.apsb.2020.02.008
10.1016/j.apsb.2020.02.008 · External reference
10.1016/j.apsb.2020.08.014
10.1016/j.apsb.2020.08.014 · External reference
10.1016/j.ejphar.2020.173705
10.1016/j.ejphar.2020.173705 · External reference
10.1128/jvi.78.24.13600-13612.2004
10.1128/jvi.78.24.13600-13612.2004 · External reference
10.1107/s2052252520009653
10.1107/s2052252520009653 · External reference
The use of knowledge management tools in viroinformatics. Example study of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a therapeutic target
10.1016/j.compbiomed.2020.103963 · 2020 · External reference
10.1016/j.tim.2017.11.011
10.1016/j.tim.2017.11.011 · External reference
10.1038/s41586-020-2601-5
10.1038/s41586-020-2601-5 · External reference
Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches
10.1016/j.jpha.2020.08.012 · 2020 · External reference
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease
10.1080/07391102.2020.1784291 · 2021 · External reference
10.1126/sciadv.abd4596
10.1126/sciadv.abd4596 · External reference
Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation
10.1007/s11224-020-01665-y · 2021 · External reference
Repurposing known drugs as covalent and non-covalent inhibitors of the SARS-CoV-2 papain-like protease
10.3389/fchem.2020.594009 · 2020 · External reference
10.1021/acs.jcim.0c01457
10.1021/acs.jcim.0c01457 · External reference
Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies
10.1016/j.drudis.2015.05.005 · 2015 · External reference
Characterization and noncovalent inhibition of the deubiquitinase and delSGylase activity of SARS-CoV-2 papain-like protease
10.1021/acsinfecdis.0c00168 · 2020 · External reference
10.1016/j.heliyon.2020.e05558
10.1016/j.heliyon.2020.e05558 · External reference
10.1038/s41467-021-21060-3
10.1038/s41467-021-21060-3 · External reference
Structure-based screening to discover new inhibitors for papain-like proteinase of SARS-CoV-2: An in silico study
10.1021/acs.jproteome.0c00836 · 2021 · External reference
High-throughput screening and quantum mechanics for identifying potent inhibitors against Mac1 domain of SARS-CoV-2 Nsp3
2021 · External reference
10.1007/s10930-020-09942-9
10.1007/s10930-020-09942-9 · External reference
Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1 pp domain inhibitor: an in silico study
10.1016/j.compbiomed.2020.104185 · 2021 · External reference
10.1002/slct.202001419
10.1002/slct.202001419 · External reference
10.1021/acs.jmedchem.5b01684
10.1021/acs.jmedchem.5b01684 · External reference
10.1093/bib/bbab044
10.1093/bib/bbab044 · External reference
10.1093/nar/gkz499
10.1093/nar/gkz499 · External reference
10.1177/2472555220960428
10.1177/2472555220960428 · External reference
10.1038/s41586-020-2223-y
10.1038/s41586-020-2223-y · External reference
10.1038/s41598-021-88630-9
10.1038/s41598-021-88630-9 · External reference
Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases
2021 · External reference
10.1074/jbc.m310875200
10.1074/jbc.m310875200 · External reference
10.1126/science.abb3405
10.1126/science.abb3405 · External reference
Polyphenols, oral health and disease: a review
10.1016/j.jdent.2009.02.003 · 2009 · External reference
Identification of polyphenols from Broussonetia papyrifera as SARS CoV-2 main protease inhibitors using in silico docking and molecular dynamics simulation approaches
2020 · External reference
Depicting the inhibitory potential of polyphenols from Isatis indigotica root against the main protease of SARS CoV-2 using computational approaches
2020 · External reference
Phytochemicals of rhus spp. as potential inhibitors of the SARS-CoV-2 main protease: molecular docking and drug-likeness study
10.1155/2021/8814890 · 2021 · External reference
A review on the alkaloids an important therapeutic compound from plants
2017 · External reference
In silico analysis of selected alkaloids against main protease (Mpro) of SARS-CoV-2
10.1016/j.cbi.2020.109309 · 2020 · External reference
The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation
10.1080/10934529.2020.1826192 · 2020 · External reference
Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants
2021 · External reference
10.3945/an.110.000117
10.3945/an.110.000117 · External reference
10.3390/molecules24213961
10.3390/molecules24213961 · External reference
Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of euphorbia neriifolia
2012 · External reference
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
10.1016/s0140-6736(03)13615-x · 2003 · External reference
10.3390/biom11010074
10.3390/biom11010074 · External reference
10.1080/14756366.2019.1690480
10.1080/14756366.2019.1690480 · External reference
10.1039/d0ra03582c
10.1039/d0ra03582c · External reference
Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
10.1080/14756366.2020.1801672 · 2020 · External reference
10.1080/14756366.2021.1873977
10.1080/14756366.2021.1873977 · External reference
Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2
2020 · External reference
10.1016/j.ijbiomac.2020.07.235
10.1016/j.ijbiomac.2020.07.235 · External reference
Identification of potential inhibitors of SARS-CoV-2 main protease and spike receptor from 10 important spices through structure-based virtual screening and molecular dynamic study
2020 · External reference
10.1371/journal.pone.0240653
10.1371/journal.pone.0240653 · External reference
Inhibition of SARS-CoV-2 main protease by phenolic compounds from Manilkara hexandra (Roxb.) Dubard assisted by metabolite profiling and in silico virtual screening
10.1039/d0ra05679k · 2020 · External reference
10.1039/d0cp03867a
10.1039/d0cp03867a · External reference
Flavonoids: an overview
10.1017/jns.2016.41 · 2016 · External reference
Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: an in-silico perspective of therapeutic targets against COVID-19 pandemic
2020 · External reference
Docking characterization and in vitro inhibitory activity of flavan-3-ols and dimeric proanthocyanidins against the main protease activity of SARS-Cov-2
10.3389/fpls.2020.601316 · 2020 · External reference
10.1111/nph.16425
10.1111/nph.16425 · External reference
10.1111/tpj.14515
10.1111/tpj.14515 · External reference
10.1002/ptr.6802
10.1002/ptr.6802 · External reference
10.1080/07391102.2020.1779818
10.1080/07391102.2020.1779818 · External reference
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease
2021 · External reference
10.1016/j.ijbiomac.2021.02.012
10.1016/j.ijbiomac.2021.02.012 · External reference
Tea polyphenols EGCG and theaflavin inhibit the activity of SARS-CoV-2 3CL-Protease in vitro
10.1155/2020/5630838 · 2020 · External reference
10.1016/j.bmc.2010.09.035
10.1016/j.bmc.2010.09.035 · External reference
Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of Torreya nucifera leaves
2020 · External reference
10.1093/bib/bbaa382
10.1093/bib/bbaa382 · External reference
Glossary of phytoconstituents: can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease
10.1016/j.fct.2021.112057 · 2021 · External reference
Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor
2020 · External reference
Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19
10.1007/s11030-020-10118-x · 2021 · External reference
10.1080/07391102.2020.1766572
10.1080/07391102.2020.1766572 · External reference
10.1093/bib/bbaa428
10.1093/bib/bbaa428 · External reference
Moroccan medicinal plants as inhibitors against SARS-CoV-2 main protease: computational investigations
10.1080/07391102.2020.1758790 · 2021 · External reference
Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
10.1016/j.jpha.2020.03.009 · 2020 · External reference
10.1016/j.lfs.2020.117831
10.1016/j.lfs.2020.117831 · External reference
10.1016/j.compbiomed.2020.104046
10.1016/j.compbiomed.2020.104046 · External reference
10.4062/biomolther.2016.181
10.4062/biomolther.2016.181 · External reference
Marine pharmacology in 2007–8: Marine compounds with antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the immune and nervous system, and other miscellaneous mechanisms of action
2011 · External reference
10.3390/md18040225
10.3390/md18040225 · External reference
10.3390/molecules26040936
10.3390/molecules26040936 · External reference
10.1080/07391102.2020.1769733
10.1080/07391102.2020.1769733 · External reference
The natural products atlas: an open access knowledge base for microbial natural products discovery
10.1021/acscentsci.9b00806 · 2019 · External reference
10.3390/microorganisms8070970
10.3390/microorganisms8070970 · External reference
Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation
10.1016/j.bpc.2020.106425 · 2020 · External reference
Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors
2021 · External reference
Cyanobacterial metabolites as promising drug leads against the Mpro and PLpro of SARS-CoV-2: an in silico analysis
2020 · External reference
10.1038/nrd1468
10.1038/nrd1468 · External reference
10.1038/nrd.2018.168
10.1038/nrd.2018.168 · External reference
10.1111/bph.13798
10.1111/bph.13798 · External reference
Challenges and opportunities of drug repositioning
10.1016/j.tips.2013.03.004 · 2013 · External reference
ETCM: an encyclopaedia of traditional Chinese medicine
10.1093/nar/gky987 · 2019 · External reference
10.1021/acscentsci.1c00039
10.1021/acscentsci.1c00039 · External reference
10.1016/j.cbi.2020.109348
10.1016/j.cbi.2020.109348 · External reference
10.1126/science.abb4489
10.1126/science.abb4489 · External reference
10.3390/ijms21093099
10.3390/ijms21093099 · External reference
10.1016/j.str.2021.06.002
10.1016/j.str.2021.06.002 · External reference
10.1021/acsinfecdis.0c00815
10.1021/acsinfecdis.0c00815 · External reference
10.1080/07391102.2020.1779819
10.1080/07391102.2020.1779819 · External reference
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
10.1038/s42003-020-01577-x · 2021 · External reference
10.1021/acsomega.0c04808
10.1021/acsomega.0c04808 · External reference
Reprofiling of approved drugs against SARS-CoV-2 main protease: an in-silico study
2020 · External reference
10.1016/j.arcmed.2020.09.013
10.1016/j.arcmed.2020.09.013 · External reference
Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors
2020 · External reference
SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs
2020 · External reference
10.1021/acscombsci.0c00140
10.1021/acscombsci.0c00140 · External reference
Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
10.1016/j.compbiolchem.2020.107325 · 2020 · External reference
Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2
2020 · External reference
10.1016/j.jiph.2020.06.016
10.1016/j.jiph.2020.06.016 · External reference
Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease
10.1016/j.micpath.2020.104546 · 2020 · External reference
10.1039/d0cp04326e
10.1039/d0cp04326e · External reference
FDA-approved antiviral and anti-infection agents as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study
10.1016/j.jiph.2021.01.016 · 2021 · External reference
10.1016/j.lfs.2020.117627
10.1016/j.lfs.2020.117627 · External reference
10.1021/acs.jproteome.0c00383
10.1021/acs.jproteome.0c00383 · External reference
10.3390/ijms21113793
10.3390/ijms21113793 · External reference
10.1021/acsmedchemlett.0c00521
10.1021/acsmedchemlett.0c00521 · External reference
10.1080/14756366.2020.1850710
10.1080/14756366.2020.1850710 · External reference
10.1016/j.csbj.2020.03.025
10.1016/j.csbj.2020.03.025 · External reference
10.1016/j.ijbiomac.2020.08.166
10.1016/j.ijbiomac.2020.08.166 · External reference
Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study
10.1039/d0ra10674g · 2021 · External reference
Computational insights on the potential ofsSome NSAIDs for treating COVID-19: priority set and lead optimization
10.3390/molecules26123772 · 2021 · External reference
10.1016/j.heliyon.2020.e05641
10.1016/j.heliyon.2020.e05641 · External reference
10.1021/acs.jcim.1c00355
10.1021/acs.jcim.1c00355 · External reference
Identification of potential inhibitors of 3CL protease of SARS-CoV-2 from ZINC database by molecular docking-based virtual screening
10.3389/fmolb.2020.603037 · 2020 · External reference
In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (M pro) of SARS-CoV-2, a causative agent COVID-19
2020 · External reference
Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
10.1093/bioinformatics/btaa224 · 2020 · External reference
Potential inhibitors for novel coronavirus protease identified by virtual screening of 606 million compounds
10.3390/ijms21103626 · 2020 · External reference
1,2,4 triazolo 1,5-a pyrimidin-7-ones as novel SARS-CoV-2 Main protease inhibitors: in silico screening and molecular dynamics simulation of potential COVID-19 drug candidates
10.1016/j.bpc.2020.106478 · 2020 · External reference
10.1016/j.molliq.2021.115636
10.1016/j.molliq.2021.115636 · External reference
Computational prediction of potential inhibitors of the main protease of SARS-CoV-2
10.3389/fchem.2020.590263 · 2020 · External reference
10.1016/j.molstruc.2021.129953
10.1016/j.molstruc.2021.129953 · External reference
Theoretical insights into the anti-SARS-CoV-2 activity of chloroquine and its analogs and in silico screening of main protease inhibitors
10.1021/acs.jproteome.0c00683 · 2020 · External reference
10.1080/07391102.2020.1776158
10.1080/07391102.2020.1776158 · External reference
10.1093/bib/bbab045
10.1093/bib/bbab045 · External reference
10.1016/j.virusres.2020.198102
10.1016/j.virusres.2020.198102 · External reference
Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2
2020 · External reference
Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease
2020 · External reference
10.1021/acs.jcim.0c00546
10.1021/acs.jcim.0c00546 · External reference
In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors
2020 · External reference
10.3390/molecules25215172
10.3390/molecules25215172 · External reference
Drug repurposing and polypharmacology to fight SARS-CoV-2 through inhibition of the main protease
10.3389/fphar.2021.636989 · 2021 · External reference
Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease
10.1002/2211-5463.12875 · 2020 · External reference
Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis
10.6026/97320630016301 · 2020 · External reference
COVID-19: rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main protease inhibitor
10.7150/ijms.48053 · 2020 · External reference
10.1073/pnas.2010470117
10.1073/pnas.2010470117 · External reference
10.1039/d0md00282h
10.1039/d0md00282h · External reference
10.1016/j.jmgm.2020.107730
10.1016/j.jmgm.2020.107730 · External reference
Targeting the main protease of SARS-CoV-2: from the establishment of high throughput screening to the design of tailored inhibitors
10.1002/anie.202016961 · 2021 · External reference
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
10.1038/s41594-020-0440-6 · 2020 · External reference
10.1126/sciadv.abd0345
10.1126/sciadv.abd0345 · External reference
10.1021/acsptsci.0c00130
10.1021/acsptsci.0c00130 · External reference
10.1016/j.bpc.2021.106610
10.1016/j.bpc.2021.106610 · External reference
Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode
10.1016/j.scib.2020.10.018 · 2021 · External reference
Prospective role of peptide-based antiviral therapy against the pain Protease of SARS-CoV-2
10.3389/fmolb.2021.628585 · 2021 · External reference
10.1016/j.crstbi.2020.12.001
10.1016/j.crstbi.2020.12.001 · External reference
Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads
2020 · External reference
10.1016/j.ejphar.2021.174082
10.1016/j.ejphar.2021.174082 · External reference
Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases
10.1186/s13578-021-00564-x · 2021 · External reference
Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation
10.1080/07391102.2020.1779130 · 2021 · External reference
Targeting 3CLpro and SARS-CoV-2 RdRp by amphimedon sp. metabolites: a computational study
10.3390/molecules26123775 · 2021 · External reference
10.1039/d1ra03937g
10.1039/d1ra03937g · External reference
10.1016/j.bmcl.2021.128099
10.1016/j.bmcl.2021.128099 · External reference
10.3390/biology10050389
10.3390/biology10050389 · External reference
Docking of fda approved drugs targeting nsp-16, n-protein and main protease of sars-cov-2 as dual inhibitors
10.33263/briac113.98489861 · 2020 · External reference
Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin
2020 · External reference
In silico screening of natural compounds as potential inhibitors of SARS-CoV-2 main protease and Spike RBD: targets for COVID-19
10.3389/fmolb.2020.599079 · 2021 · External reference
10.1016/j.chmed.2021.06.002
10.1016/j.chmed.2021.06.002 · External reference
